SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- Cue Health
("Cue") (Nasdaq: HLTH), a healthcare technology company, today
announced its first airline partnership with Air Canada to provide
U.S.-based passengers with access to Cue's molecular COVID-19 test:
the most accurate* self-test on the market.
Air Canada's U.S.-based customers can now meet
Canada's specific travel testing
requirements using Cue's COVID-19 tests, which can be
purchased three, six, or 10 at a time along with the reusable and
portable Cue Cartridge Reader, which processes test results in
about 20 minutes. Under this partnership, each Cue test comes with
access to a video proctoring session within the Cue Health App. The
companies are working to create a fully French/English bilingual
experience and expect to make the service available to Air Canada's
Canadian-based customers in early 2022.
As a Nucleic Acid Amplification Test (NAAT), Cue's molecular
COVID-19 test meets Canada's
testing entry requirements, as Canada is one of the growing number of
countries that accept molecular NAAT test results for entry.
These travel entry requirements are more stringent than those
countries that accept rapid antigen test results.
"To meet the COVID-19 testing needs of modern travelers today,
we are proud to be able to offer the premier at-home testing
solution for COVID-19, which is not only the most accurate but is
also convenient, fast, and easy to use," said Clint Sever, Co-Founder and Chief Product
Officer of Cue. "Together with Air Canada, we can now equip
U.S. passengers with access to their health information in
real-time, providing people with much-needed peace of mind before
and after their flights."
"Air Canada is a leader in adopting and implementing
science-based safety measures to simplify travel journeys," said
Mark Nasr, Senior Vice President,
Products Marketing & eCommerce of Air Canada. "Together
with Cue Health, we're excited to extend our industry-leading range
of testing options that make travelling easier and more
predictable. Cue Health's sophisticated, slick and reusable Reader
is the perfect solution for frequent travelers, families, and
groups."
Testing requirements vary from country to country and are
constantly evolving. It is critical that travelers check the Travel
Ready hub at aircanada.com/travelready to ensure they have the most
up-to-date country-specific requirements before they travel.
Cue has received Interim Order authorization from Health Canada
to sell and distribute its COVID-19 test for both point-of-care and
self-testing.
Last month, Cue launched its direct-to-consumer (DTC) virtual
health platform in the United
States, making Cue's first-of-its-kind molecular COVID-19
test available through Cue's new eCommerce site and
in-app shop. Cue's COVID-19 test is able to detect the
Omicron variant and can be used on adults and children (2 years and
over), with or without symptoms, wherever they are. Cue offers
same-day delivery of products in a growing number of major markets
in the U.S. Cue's new membership offering, Cue+™ Complete, provides
broad travel entry coverage with molecular NAAT tests and
supervised testing via video proctoring. Cue's virtual care and
online proctoring services are available to Cue's U.S. customers 24
hours per day.
Cue's molecular COVID-19 test provides highly accurate,
lab-quality results -- including detection of Omicron and other
known variants -- in just 20 minutes. Cue has already delivered
millions of COVID-19 tests, which are being used in thousands of
settings where a highly accurate testing solution is required,
including schools, nursing homes, correctional facilities,
hospitals, and community health clinics. Cue also provides tests to
other world-class organizations like Mayo Clinic, Google, the
National Basketball Association (NBA), and Major League Baseball
(MLB), among many others.
About Cue Health
Cue Health (Nasdaq: HLTH) is a
healthcare technology company that makes it easy for individuals to
access health information and places diagnostic information at the
center of care. Cue Health enables people to manage their health
through real-time, actionable, and connected health information,
offering individuals and their healthcare providers easy access to
lab-quality diagnostics anywhere, anytime, in a device that fits in
the palm of the hand. Cue Health's first-of-its-kind COVID-19 test
was the first FDA-authorized molecular diagnostic test for at-home
and over-the-counter use without a prescription and physician
supervision. Outside the United
States, Cue Health has received the CE mark in the European
Union, Interim Order authorization from Health Canada, regulatory
approval from India's Central
Drugs Standard Control Organisation, and PSAR authorization from
Singapore's Health Sciences
Authority. Cue was founded in 2010 and is headquartered in
San Diego. For more information,
please visit www.cuehealth.com.
Forward-Looking Statements
Statements in this press
release about future expectations, plans and prospects, as well as
any other statements regarding matters that are not historical
facts, may constitute "forward-looking statements". The words,
without limitation, "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "will," "would" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these or similar identifying words. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including the factors
discussed in the "Risk Factors" section of the Form 10-Q dated
November 10, 2021 filed by Cue with
the SEC. Any forward-looking statements contained in this press
release are based on the current expectations of Cue's management
team and speak only as of the date hereof, and Cue specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
The Cue COVID-19 Test for Home and Over The Counter (OTC) Use
has not been FDA cleared or approved; but has been authorized by
FDA under an Emergency Use Authorization (EUA). This product has
been authorized only for the detection of nucleic acid from
SARS-CoV-2, not for any other viruses or pathogens. The emergency
use of this product is only authorized for the duration of the
declaration that circumstances exist justifying the authorization
of emergency use of in vitro diagnostics for detection and/or
diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food,
Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the
declaration is terminated or authorization is revoked sooner.
*Based on clinical study results submitted to FDA for other
EUA molecular home tests.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/first-of-its-kind-cue-health-partnership-with-air-canada-provides-us-based-customers-with-special-access-to-the-most-accurate-covid-19-self-test-301448909.html
SOURCE Cue Health Inc.